Takeda Drops Orteronel Prostate Cancer Drug After Phase III Trials
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said it is dropping its TAK-700 (orteronel) drug for treating prostate cancer because it proved no better than alternatives in two Phase III trials in the U.S. and Europe.